Posted on January 13th, 2010 by
In addition to providing information about risk of distant breast cancer recurrence, the Oncotype DX® Recurrence Score also provides information about risk of local or regional breast cancer recurrence. These results were published in the Journal of Clinical Oncology.
Oncotype DX is a genomic test that has been shown to predict the likelihood of distant cancer recurrence and the likelihood of chemotherapy benefit in women with early-stage, estrogen receptor-positive breast cancer that is treated with hormonal therapy. The test evaluates the activity of 21 genes from a sample of the patient’s cancer to determine the patient’s Recurrence Score. Oncotype DX has been added to U.S. medical guidelines for early-stage breast cancer.
Although the Oncotype DX Recurrence Score has been shown to predict the risk of distant cancer recurrence, there has been less information about whether it also predicts risk of local or regional recurrence (recurrence in or near the breast).
To evaluate the Recurrence Score in relation to risk of local and regional breast cancer recurrence, researchers evaluated information from 895 women treated with tamoxifen [Nolvadex®], 355 women treated with placebo, and 424 patients treated with chemotherapy plus tamoxifen. All of the women had node-negative, estrogen receptor-positive breast cancer.
These results indicate that in addition to predicting the risk of distant cancer recurrence, the Recurrence Score also predicts the risk of local or regional cancer recurrence in women with node-negative, estrogen receptor-positive breast cancer.
Reference: Mamounas EP, Tang G, Fisher B et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. Journal of Clinical Oncology. [early online publication] January 11, 2010.
You must be logged-in to the site to post a comment.